In 2014, MAPS spun out a individual division to immediate exploration and put together for an eventual FDA application, which it submitted at the conclusion of past calendar year. In early 2024, that offshoot was renamed Lykos Therapeutics.Pseudohallucinations: it doesn't bring about hallucinations for each se but makes illusions by altering the se